- Home
- KALV vs MEGI Comparison
KALV vs MEGI Comparison
Compare KALV & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- MEGI
- Stock Information
- Founded
- KALV N/A
- MEGI 2021
- Country
- KALV United States
- MEGI United States
- Employees
- KALV N/A
- MEGI N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- MEGI Investment Managers
- Sector
- KALV Health Care
- MEGI Finance
- Exchange
- KALV Nasdaq
- MEGI Nasdaq
- Market Cap
- KALV 637.9M
- MEGI 749.0M
- IPO Year
- KALV N/A
- MEGI N/A
- Fundamental
- Price
- KALV $15.82
- MEGI $14.29
- Analyst Decision
- KALV Strong Buy
- MEGI
- Analyst Count
- KALV 9
- MEGI 0
- Target Price
- KALV $26.29
- MEGI N/A
- AVG Volume (30 Days)
- KALV 734.1K
- MEGI 178.0K
- Earning Date
- KALV 09-09-2025
- MEGI 01-01-0001
- Dividend Yield
- KALV N/A
- MEGI 11.40%
- EPS Growth
- KALV N/A
- MEGI N/A
- EPS
- KALV N/A
- MEGI N/A
- Revenue
- KALV N/A
- MEGI N/A
- Revenue This Year
- KALV N/A
- MEGI N/A
- Revenue Next Year
- KALV $221.95
- MEGI N/A
- P/E Ratio
- KALV N/A
- MEGI N/A
- Revenue Growth
- KALV N/A
- MEGI N/A
- 52 Week Low
- KALV $7.30
- MEGI $10.63
- 52 Week High
- KALV $16.32
- MEGI $14.89
- Technical
- Relative Strength Index (RSI)
- KALV 71.16
- MEGI 45.33
- Support Level
- KALV $13.72
- MEGI $14.28
- Resistance Level
- KALV $13.96
- MEGI $14.62
- Average True Range (ATR)
- KALV 0.69
- MEGI 0.16
- MACD
- KALV 0.31
- MEGI -0.02
- Stochastic Oscillator
- KALV 99.15
- MEGI 19.51
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.